Compare Grab Holdings Ltd. (GRAB) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs ResMed Inc. — how do they compare? Grab Holdings Ltd. trades at $3.19 (market cap $12.72B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 2.5× Grab Holdings Ltd.'s market cap, and ResMed Inc. pays a 1.16% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and ResMed Inc. for 51 Days on average.
| GRAB | RMD | |
|---|---|---|
Market Cap | $12.72B | $31.89B |
Volume | 65,352,859 | 618,314 |
Sector | Technology | Health |
52-Week High | $6.12 | $275.96 |
52-Week Low | $2.80 | $182.82 |
Typical Hold Time | 94 Days | 51 Days |
Enterprise Value | $8.46B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB Holdings trades at $3.11, up 0.97% with a bearish technical signal despite recent earnings beats. The company achieved profitability in 2025 with $268M net income and maintains strong analyst support (91.67% buy ratings). Recent developments include a $1.49B acquisition of Atome Financial and $30M in insider buying, though the stock faces headwinds from regional protests and competitive pressures.
GRAB's transition to profitability and Southeast Asian expansion present growth opportunities, but investors face risks from aggressive capital deployment, regulatory challenges, and volatile cash flow patterns. The stock's current valuation metrics (P/E 28.27, P/S 3.81) reflect optimism about future earnings potential despite near-term technical weakness.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
